Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Lipid</td><td class="align_center">(mg/g)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Cholesterol (Chol)</td><td class="align_center">11.5</td></tr><tr><td class="align_left">Ethanolamine ether phospholipid (ePE)</td><td class="align_center">42.6</td></tr><tr><td class="align_left">Choline ether phospholipid (ePC)</td><td class="align_center">34.2</td></tr><tr><td class="align_left">Ceramide aminoethylphosphonate (CAEP)</td><td class="align_center">10.6</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Lipid composition of purified ether phospholipids from scallop.</div>

Parkinson’s Disease

tab1

Table 1

Table 1: Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report 

Table 1 | Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report 